Danish pharmaceutical giant Novo Nordisk (NOVOb.CO) has announced a significant operational shift, adopting ‘Novo’ as its day-to-day name and introducing a new cultural strategy. The company is a prominent Danish drugmaker. It is widely known for its extensive portfolio in diabetes and obesity treatments. These changes are being enacted as the firm endeavours to claw back ground in the fiercely competitive global obesity drug race. While its legal name will remain ‘Novo Nordisk A/S’, the firm is slated to unveil further details on its broader business strategy during an upcoming Capital Markets Day on September 21.
Central to this organisational overhaul is “The Novo Way,” a new cultural strategy founded on four key principles: customer obsession, competitiveness, clarity, and care and integrity. This internal reorientation is a direct response to considerable external pressures. Novo Nordisk is currently navigating intense rivalry from other major players, notably Eli Lilly, in the weight-loss drug sector, in addition to significant investor expectations for the consistent delivery of new blockbuster medications and robust advancements in its product pipeline.
The firm’s market performance reflects these challenges. Despite its oral GLP-1 product reportedly outperforming Eli Lilly by hundreds of thousands of weekly U.S. prescriptions, according to analyst-provided IQVIA data, the company’s Copenhagen-listed shares are down nearly 15% this year. These commercial gains have unfortunately been overshadowed by persistent pipeline difficulties, most recently underscored by last week’s decision to scrap two late-stage trials for its experimental heart drug, ziltivekimab, further impacting investor confidence.
